Literature DB >> 28465114

Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: What are the risk factors?

Yoshitaka Kimura1, Takashi Noda2, Taka-Aki Matsuyama3, Yosuke Otsuka4, Tsukasa Kamakura4, Mitsuru Wada4, Kohei Ishibashi4, Yuko Inoue4, Koji Miyamoto4, Hideo Okamura4, Satoshi Nagase4, Takeshi Aiba4, Shiro Kamakura4, Teruo Noguchi4, Toshihisa Anzai4, Kazuhiro Satomi5, Yuko Wada6, Seiko Ohno6, Minoru Horie6, Wataru Shimizu7, Satoshi Yasuda4, Hiroaki Shimokawa8, Kengo Kusano4.   

Abstract

BACKGROUND: We previously demonstrated that heart failure (HF) was one of the major causes of death in arrhythmogenic right ventricular cardiomyopathy (ARVC). The purpose of this study was to elucidate the clinical impact and risk factors of HF in patients with ARVC. METHODS AND
RESULTS: We evaluated cardiac adverse outcomes including HF in 113 consecutive patients with ARVC (85 men, mean age: 44±15years). During a median follow-up of 10.0years (interquartile range: 5.2 to 15.7years), 29 patients (26%) were hospitalized for progressive HF. The patients with one or more episodes of HF hospitalization had about a 10-fold increased incidence of cardiac death (14/29 [48%] vs. 4/84 [4.7%], p<0.0001). Left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) were significantly lower in the patients with HF hospitalization compared to the patients without HF hospitalization (LVEF, 45±15 vs. 54±13%, p=0.001; RVEF, 26±10 vs. 33±11%, p=0.003, respectively). Regarding the ECG findings, the prevalence of first-degree atrioventricular block (AVB, PR interval >200ms) and epsilon waves were significantly higher in patients with HF hospitalization than those without HF hospitalization (first-degree AVB, 14/29 [48%] vs. 11/84 [13%], p<0.0001; epsilon waves, 10/29 [34%] vs. 12/84 [14%], p=0.02). In multivariate analysis, first-degree AVB at baseline was the strongest independent risk factor for HF hospitalization in patients with ARVC (hazard ratio 4.24, 95% confidence interval 1.79-10.47, p=0.0011).
CONCLUSION: HF hospitalization has a significant relation with malignant clinical course in ARVC patients. First-degree AVB was an independent determinant for increased risk of HF hospitalization.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arrhythmogenic right ventricular cardiomyopathy; Atrial arrhythmias; First-degree atrioventricular block; Heart failure

Mesh:

Year:  2017        PMID: 28465114     DOI: 10.1016/j.ijcard.2017.04.061

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Prevalence and characteristics of the Brugada electrocardiogram pattern in patients with arrhythmogenic right ventricular cardiomyopathy.

Authors:  Nobuhiko Ueda; Satoshi Nagase; Naoya Kataoka; Kenzaburo Nakajima; Tsukasa Kamakura; Mitsuru Wada; Kenichiro Yamagata; Kohei Ishibashi; Yuko Inoue; Koji Miyamoto; Takashi Noda; Takeshi Aiba; Chisato Izumi; Teruo Noguchi; Seiko Ohno; Kengo Kusano
Journal:  J Arrhythm       Date:  2021-08-30

2.  Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Shi Chen; Liang Chen; Ardan M Saguner; Kai Chen; Deniz Akdis; Alessio Gasperetti; Corinna Brunckhorst; Hanwei Tang; Guangran Guo; Man Rao; Xiangjie Li; Jiangping Song; Firat Duru; Shengshou Hu
Journal:  J Am Heart Assoc       Date:  2022-06-29       Impact factor: 6.106

Review 3.  Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in clinical practice.

Authors:  Ka Hou Christien Li; George Bazoukis; Tong Liu; Guangping Li; William K K Wu; Sunny Hei Wong; Wing Tak Wong; Yat Sun Chan; Martin C S Wong; Katharina Wassilew; Vassilios S Vassiliou; Gary Tse
Journal:  J Arrhythm       Date:  2017-12-21

4.  Prognostic Implication of First-Degree Atrioventricular Block in Patients With Hypertrophic Cardiomyopathy.

Authors:  Satoshi Higuchi; Yuichiro Minami; Morio Shoda; Shota Shirotani; Chihiro Saito; Shintaro Haruki; Masayuki Gotou; Daigo Yagishita; Koichiro Ejima; Nobuhisa Hagiwara
Journal:  J Am Heart Assoc       Date:  2020-03-09       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.